Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?
Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.